Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

CYCC stock opened at $0.22 on Wednesday. The company has a market cap of $44.87 million, a P/E ratio of -0.02 and a beta of 0.15. Cyclacel Pharmaceuticals has a 1 year low of $0.17 and a 1 year high of $4.00. The stock’s fifty day moving average price is $0.29 and its 200-day moving average price is $0.44.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings results on Wednesday, April 2nd. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million.

Insider Transactions at Cyclacel Pharmaceuticals

In related news, CEO David E. Lazar sold 194,628,820 shares of the firm’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 68.00% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.